Maravai LifeSciences Holdings, Inc. (MRVI): what the price assumes

In the published model solve dated 2026-Q2, anchored at $6.40, Maravai LifeSciences Holdings, Inc. (MRVI) is priced for today's economics sustained for ~9.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/MRVI

Headline

FieldValue
TickerMRVI
CompanyMaravai LifeSciences Holdings, Inc.
Current price$6.40/sh
CompositionTriLink 64% / Cygnus 36%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)9.5%
Operating margin (mid-cycle)16.8%
Margin compression (value-band)-7.3pp
Trailing margin (depressed year)-82.2%
Must persist for9.4y
Multiple paid32x mid-cycle operating income

The operating-margin figure is value-band context at year 9: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

Reconcile: at the x-ray's 9.3% required return this reads ~6.4 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.70σ
sustained it ~9.4 years at this level17%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset4.68x2expensive
Earnings—0—
Relative—0—
Growth—0—

Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.

Per-Model Detail (n=2)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative——noP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$1.444.44xyesReference only (book value floor): BV/sh $1.44, ROE negative
Two-Stage Excess ReturnAsset$1.304.92xyesReference only (book value with convergence): BV/sh $1.44, ROE converges to ke
Discounted Future Market CapGrowth$2.872.23xnoRev $0.2B, growth -11% (input: historical growth; tapered), Terminal P/S: 3.9x / 4.6x / 5.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$10.990.58xnoNormalized EBIT (5y avg op income, one-time charges added back) $0.16B × (1−21%) / WACC 7.7% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——noRevenue $0.20B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
TriLinkoperatingenterprise$119.8m—withheldunresolved no unit value
Cygnusoperatingenterprise$66.0m—withheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$105.9m
Net debt / NOPAT (after-tax)3.91x
Net debt / operating income (pre-tax)3.09x
Interest coverage1.3x
Share count CAGR (dilution)3.5%
Burning cashyes

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 16.8%); the trailing year was depressed.

Bullet Takeaways

The single decisive number is the EBITDA swing. Q1 2026 adjusted EBITDA turned positive at $20.3 million from a $10.5 million loss a year earlier, and free cash flow went positive, the clearest sign Maravai's downcycle has bottomed.

The revenue inflection is real but mixed. Q1 revenue rose 40.5% to $65.8 million, led by TriLink, though a large chunk came from volatile high-volume CleanCap orders for commercial COVID vaccines rather than the steadier base business.

The valuation already prices a recovery. At $5.18 the market pays roughly 27x mid-cycle operating income while the company still posts GAAP operating losses, carries a book value near $1.44 per share, and recently took goodwill and intangible impairments. The price assumes the rebound holds and extends.

Bull Case

The metric that decides this thesis is adjusted EBITDA, and it just flipped. In Q1 2026 Maravai's adjusted EBITDA turned positive at $20.3 million from a loss of $10.5 million a year earlier, and free cash flow improved to positive $4.2 million from negative $13.9 million. For a company whose trailing operating income is still deeply negative, the swing to positive cash generation is the single most important signal that the downcycle in life-science tools and mRNA inputs has bottomed and the operating leverage is starting to work in reverse.

The revenue line confirms the turn. Q1 revenue rose 40.5% to $65.8 million, with TriLink, the proprietary CleanCap and modified-RNA business, delivering $47.5 million. The filing attributes the strength directly to its core technology, noting results "were significantly and positively impacted by high-volume sales of our proprietary CleanCap analogs and highly modified RNA products, particularly mRNA, for commercial vaccines" (FY2025 10-K, accession 0001823239-26-000011). Encouragingly, the recovery is broadening: TriLink base, non-COVID revenue grew 15% year over year even as total TriLink revenue grew 65%, so the franchise is not solely a COVID story.

Management is confident enough to raise the outlook. Maravai lifted full-year 2026 guidance to revenue of $205 to $215 million and adjusted EBITDA of $30 to $32 million, above prior ranges. The company sits in a structurally growing market, supplying the nucleic-acid building blocks behind mRNA medicines and diagnostics, and the inversion deliberately prices it on through-the-cycle margins rather than the trough because trailing earnings are cyclically depressed. With liquid assets of about $166 million against manageable debt, the bull case is a specialized input supplier whose cash generation has inflected positive at the bottom of its cycle, with a raised outlook and a broadening revenue base.

Bear Case

The disconnect between price and fundamentals is the qualitative problem to face first: Maravai is being valued as a recovered company while it is still a loss-making one mid-recovery. The price pays for an eight-year run of through-cycle compounding, but the company just wrote down a large part of its own acquired value. The filing records "a goodwill impairment of $12.4 million related to the TriLink BioTechnologies reporting unit, $30.4 million related to the Alphazyme reporting unit, and intangible asset impairment of $27.8 million" (FY2025 10-K, accession 0001823239-26-000011), and notes accumulated TriLink goodwill impairment of $209 million. Impairments are management conceding the assets are worth less than paid, which sits awkwardly under a price that assumes durable growth.

The recovery leans on the most volatile part of the business. Of the Q1 revenue surge, $14.3 million came from high-volume CleanCap orders for commercial COVID-19 vaccine programs, which the company itself describes as a significant but lumpy driver. COVID-linked orders can vanish as quickly as they appear, and the broader customer base is concentrating against Maravai. The filing warns that industry consolidation has "served to create fewer customer accounts and to concentrate purchasing decisions for some customers, resulting in increased pricing pressure on us" (accession 0001823239-26-000011), and that demand depends on biotech research-and-development spending and "the funding of venture- and private equity-backed biotechnology" companies that can dry up in a tight financing environment.

The numbers underneath the price are thin. Trailing operating income is about negative $168 million, the current operating margin is roughly negative 82%, interest coverage is just 1.3x, and the company is burning cash on a trailing basis even after the recent quarterly improvement. Book value is only about $1.44 per share against a $5.18 price (June 27, 2026), so the asset floor offers little protection, and the share count has been rising about 3.5% a year. At roughly 27x normalized operating income with the reverse-DCF band at just $1.49 to $3.46, the bear case is that the market has paid a full recovery multiple for a single good quarter built partly on volatile COVID orders, with impairments and dilution as evidence the underlying business is still finding its footing.

Valuation

Maravai is priced on its through-cycle earnings power because its trailing results are deeply unprofitable. The current operating margin is about negative 82% and trailing operating income is roughly negative $168 million, so capitalizing current earnings is meaningless. On a normalized basis the inversion shows the market paying about 27x mid-cycle operating income at $5.18, which implies operating growth held near its self-funding ceiling for roughly eight years, computed at a 10.9% cost of capital. The model labels that elevated, and history agrees: only about 25% of comparable fast-growers have sustained this pace for eight years.

The X-ray methods that can run on this profile land near or below the price. The revenue-multiple relative valuation lands at $5.59, essentially at the price, on a 4x sector price-to-sales applied to trailing revenue. The book-value reference methods are far lower, near $1.30 to $1.44, reflecting a thin balance sheet after impairments. The reverse-DCF reasonable band lands at roughly $1.49 to $3.46 with a base near $2.62, below the current quote. There is also a measurement note: the trailing EDGAR operating income and the record-basis figure the inversion prices differ by more than ten percent, so the normalized view and the spot view are explicitly different bases.

The synthesis is that the price sits at or above almost every method that fits the company. The single revenue-multiple method that reaches $5.18 does so by applying a full sector multiple to a revenue base partly inflated by volatile COVID orders. The normalized inversion and the reverse-DCF band both say fair value is below the price unless the recovery proves durable and the margin expands toward its through-cycle level. The gap between the methods and the price is recovery optimism. It is a coherent bet that the EBITDA inflection extends, but it is a bet priced as if it already has, not a discount that pays for the risk that it stalls.

Catalysts

The Q1 2026 print, reported May 7, 2026, is the pivotal recent event: revenue up 40.5% to $65.8 million, adjusted EBITDA turning positive to $20.3 million from a $10.5 million loss, and free cash flow positive at $4.2 million. TriLink delivered $47.5 million including $14.3 million of high-volume CleanCap COVID-vaccine orders, while base non-COVID TriLink revenue grew 15% (Businesswire; StockTitan). Maravai raised full-year 2026 guidance to revenue of $205 to $215 million and adjusted EBITDA of $30 to $32 million.

The forward set is about whether the recovery is durable and diversified. The swing factors into the next prints are the persistence of high-volume CleanCap COVID orders versus growth in the steadier base business, biotech and pharma research-and-development funding that drives demand, pricing pressure from customer consolidation, and whether adjusted EBITDA and free cash flow stay positive as the year progresses. With the price reflecting a full recovery, the quality of the revenue mix, base versus COVID, will matter as much as the headline growth rate.

Sources: Maravai LifeSciences Q1 2026 results (Businesswire; StockTitan; MRVI 8-K, 2026); Simply Wall St and Quartr coverage (2026).

Peer Cohorts (Per Segment, With Filing Citations)

TriLink (reported)

Cygnus (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive MRVI report on boothcheck